Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Dorairaj Prabhakaran

General Cardiology

View

Dr. Pugazhendhi Vijayaraman

EP · Geisinger

View

Dr. Robert Schaller

EP · HUP

View

Dr. Trey Woods

General Cardiology · Emory Healthcare

View

Dr. Brahmajee Nallamothu

Interventional Cardiology · UMHS

View

Dr. Felix Yang

EP · NYU Langone

View

Dr. Jennifer Rymer

Interventional & Peripheral Cards · Duke University

View

Dr. Ami Bhatt

Adult Congenital Heart Disease · MGH

View

Dr. Gregory Marcus

EP · UCSF

View

Dr. Connor O'Brien

Cardiac Critical Care · UCSF Medical Center

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Intravascular Imaging-Guided Versus Angiography-Guided Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Trials.

    Jan 12, 2024DOI: 10.1161/jaha.123.031111Meta-AnalysisAHA

    Written by: Jayakumar SreenivasanRohin K ReddyYasser JamilAaqib MalikDaniel ChamieJames P HowardMichael G NannaGary S MintzAkiko MaeharaZiad A AliJeffrey W MosesShao-Liang ChenAlaide ChieffoAntonio ColomboMartin B LeonAlexandra J LanskyYousif Ahmad

    Find these authors on Roon

    AM
    Dr. Aaqib Malik
    Interventional & Complex Coronary Cards

    Methods

    The authors declare that all data used for the analyses included in this study are available within the article and the supplemental files. Any additional data not presented in this manuscript is available from the corresponding author upon reasonable request. The analysis was registered with the international prospective register of systematic reviews (PROSPERO) (CRD42023409668) and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidance.19 Institutional review board approval and informed patient consent for study participation were not required, as this study is a systematic review and meta‐analysis of previously published publicly available data in indexed databases.We performed a systematic search of the MEDLINE, Embase, and Cochrane databases from inception through March 2023 for RCTs assessing outcomes after IVUS or OCT‐guided PCI compared with angiography‐guided PCI. We also manually searched the bibliographies of previous meta‐analyses, reviews, and selected studies to identify additional eligible trials, and reviewed conference abstracts from Transcatheter Cardiovascular Therapeutics, EuroPCR, American College of Cardiology, European Society of Cardiology, and American Heart Association meetings. The searches were performed by 2 independent investigators (J.S. and A.M.). Further full‐text review was conducted by 3 independent investigators (J.S., A.M., and Y.J.) for the final assessment and inclusion of the studies that satisfy the inclusion and exclusion criteria. Any disputes or concerns were resolved by consensus and discussion with the senior author (Y.A.). Our search strings and the detailed search strategy with commands are provided in Table S1.We included only RCTs comparing intravascular imaging–guided PCI versus angiography‐guided PCI for this meta‐analysis. We included trials that compared IVUS‐guided or OCT‐guided PCI separately or in combination, with angiography alone as the reference standard, and reported at least 1 of the main outcomes as detailed below. We did not exclude any trials on the basis of sample size or duration of follow‐up. We excluded trials involving implantation of bioresorbable stents or bare metal stents. Observational studies were also not included in the present analysis. We did not include studies comparing only IVUS‐guided PCI with OCT‐guided PCI.Two investigators (J.S. and A.M.) independently extracted the clinical outcomes data and resolved any conflicts in consultation with a third independent investigator (Y.A.). The data on baseline characteristics of study participants; study characteristics; and study outcomes, including crude estimates, risk estimates, sample size, and follow‐up were extracted directly from the published articles, supplemental files, and subsequent publications, including post hoc analyses, patient‐level meta‐analyses, and subgroup analyses. The end points at the maximum available follow‐up period were extracted, adhering to the intention‐to‐treat principle if available for all included trials. The principal investigators of each trial were contacted to provide additional relevant data not reported in the publications.Risk of bias was evaluated by 2 independent investigators (J.S. and A.M.) using the Cochrane Risk of Bias Tool for the following domains: (1) random sequence generation; (2) allocation concealment; (3) blinding of participants and personnel; (4) blinding of outcome assessment; (5) incomplete outcome data; (6) selective outcome reporting; and (7) other bias. The potential source of bias in each domain was judged high or low on the basis of the study characteristics as outlined in the Cochrane Handbook for Systematic Reviews of Interventions.20 Certainty of evidence was assessed with the Grading of Recommendations, Assessment, Development, and Evaluations system.21The prespecified main outcomes of interest were MACEs, cardiac death, and all‐cause death. Most of the included trials defined MACE as a composite of cardiac death, myocardial infarction (MI), and repeat revascularization. Other clinical outcomes of interest were MI, target‐vessel revascularization (TVR), TLR, target‐vessel MI, periprocedural MI, stent thrombosis, and target‐vessel failure. The outcomes were defined as per the individual study definitions of each outcome and are summarized in Table S2. Composite outcomes were assessed only if reported by the individual trials (ie, composite rates were not obtained by summing of individual components).Outcomes were assessed on an intention‐to‐treat basis. Random‐effects meta‐analyses were performed using the restricted maximum likelihood estimator. Outcomes were assessed as relative risks (RRs) and absolute risk reductions at the last follow‐up available for each constituent trial. The number needed to treat to prevent 1 event was calculated for each outcome as the reciprocal of the absolute risk reductions.22 The I 2 statistic was used to assess heterogeneity.22 However, as the I 2 statistic measures the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error, it may be considered to be an indirect measure of heterogeneity.23 To directly quantify the presence of interstudy heterogeneity, we also performed Cochrane's Q test, and provide Q statistics calculated as the weighted sum of squared differences between individual study effects and the pooled effect across studies. Sensitivity analyses were performed with a fixed‐effect model, and a jackknife sensitivity analysis was also performed excluding each trial in turn for the main outcomes. We also performed sensitivity analyses using the Fisher exact test for all main outcomes. Publication bias was assessed with funnel plots.We performed prespecified subgroup analyses of patients undergoing PCI of a complex lesion. The complex lesion subgroup was defined as any of the following: (1) unprotected left main PCI; (2) bifurcation PCI; (3) chronic total occlusion PCI; (4) PCI involving long lesions (>28 mm); (4) multivessel PCI involving at least 2 major epicardial coronary arteries being treated at the same time; (5) PCI involving the use of multiple stents (≥3); (6) PCI of in‐stent restenosis; or (7) PCI of a severely calcified stenosis or ostial stenosis of a major epicardial coronary artery. This definition was primarily based on that used in the RENOVATE‐COMPLEX‐PCI (Randomized Controlled Trial of Intravascular Imaging Guided Versus Angiography‐Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention) trial except for stent length, as most other trials defined a long stenosis as >28 mm in length.4 An additional, stricter definition complex PCI was also used as a sensitivity analysis including left main lesions, chronic total occlusions, and the complex PCI subgroup from the ULTIMATE (Intravascular Ultrasound Guided Drug Eluting Stents Implantation in “All‐Comers” Coronary Lesions) trial (multivessel disease, bifurcation with 2 stents implanted, moderate or greater calcification, chronic total occlusion, >3 stents implanted, and total stent length >90 mm).We also performed subgroup analyses based on the type of imaging modality used (IVUS or OCT), type of clinical presentation (acute coronary syndrome versus stable coronary artery disease) and follow‐up duration of RCTs (short‐term follow‐up, <1 year; intermediate follow‐up, at least 1 year but <3 years; long‐term follow‐up, at least 3 years). Interactions between subgroups were assessed with meta‐regression using a mixed‐effects model,24 with the subgroup characteristic as a moderator and the individual trial as a random effect.25 Mean values are expressed as mean±SD unless otherwise stated. Significance testing was performed at the 2‐tailed 5% significance level. The statistical programming environment R with the metafor package was used for all statistical analyses (R Foundation for Statistical Computing, Vienna, Austria).24, 26

    Results

    The Preferred Reporting Items for Systematic Reviews and Meta‐Analyses flow diagram depicts the process of study selection (Figure S1). A total of 16 RCTs (7814 participants [imaging group, 4307; angiography group, 3507]; mean age, 64.3±2.4 years; men, 73.7±2.6%) were included.2, 4, 5, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 The weighted mean follow‐up duration was 28.8 months (range, 6 months to 5 years). Among the study population, 6026 participants underwent PCI of complex lesion subsets. Among the included trials, 9 trials exclusively used IVUS, 4 trials exclusively used OCT, and 3 trials used both IVUS and OCT for imaging‐guided PCI compared with angiography‐alone–guided PCI. The baseline characteristics of the study population of individual studies are summarized in Table 1. The procedural characteristics of each trial are reported separately in Table S3. The study inclusion and exclusion criteria are listed in Table S4. The risk‐of‐bias assessment is summarized in Table S5. All included RCTs had a low risk of bias, and hence, the overall body of evidence was judged to have a low risk of bias. Direct assessment of heterogeneity across the primary analyses with Cochrane's Q test did not reveal any significant heterogeneity, providing evidence to support the assumption that the true treatment effect of intravascular imaging in PCI is similar across trials and observed variations are likely due to chance. There was no evidence of publication bias (Figure S2). Previously unpublished additional data regarding all‐cause death obtained directly from principal investigators are summarized in Table S6. The study definitions for optimal intravascular imaging–guided stent implantation and the percentage success rate of achieving optimal stent implantation in each included trial are summarized in Table S7. The findings with assessment of certainty of evidence for each outcome are summarized in Table 2.Baseline Characteristics of Included TrialsData are presented as mean ± SD and proportions as (%). AIR‐CTO indicates angiographic and clinical comparisons of intravascular ultrasound‐ versus angiography‐guided drug‐eluting stent implantation for patients with chronic total occlusion lesions; AVIO, Angiography Vs. Intravascular Ultrasound Optimization trial; CABG, coronary artery bypass graft; CHF, congestive heart failure; CTO‐IVUS, Impact of Intravascular Ultrasound‐Guided Chronic Total Occlusion Intervention With Drug‐eluting Stents; DOCTORS, Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention in Patients with Non‐ST‐Elevation Acute Coronary Syndrome; HOME DES IVUS, Long‐Term Health Outcome and Mortality Evaluation After Invasive Coronary Treatment Using Drug Eluting Stents with or without the Intravascular Ultrasound Guidance trial; ILUMIEN III, OPTIMIZE PCI, Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation; iSIGHT, Optical Coherence Tomography Versus Intravascular Ultrasound and Angiography to Guide Percutaneous Coronary Interventions; IVUS, intravascular ultrasound; IVUS‐XPL, Effect of Intravascular Ultrasound–Guided vs Angiography‐Guided Everolimus‐Eluting Stent Implantation; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSTEMI, non–ST‐segment–elevation myocardial infarction; OCT, optical coherence tomography; OCTACS, Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Nobori Stent Implantation in Patients With Non‐ST‐Segment‐Elevation Myocardial Infarction trial; PCI, percutaneous coronary intervention; RCT, randomized controlled trial STEMI; RENOVATE‐COMPLEX‐PCI, Randomized Controlled Trial of Intravascular Imaging Guidance versus Angiography‐Guidance on Clinical Outcomes after Complex Percutaneous Coronary Intervention; RESET, Real Safety and Efficacy of a 3‐Month Dual Antiplatelet Therapy Following Zotarolimus‐Eluting Stents Implantation) trial; ROBUST, OCT guidance during stent implantation in primary PCI trial; ST‐segment, elevation myocardial infarction; UA, unstable angina; and ULTIMATE, Intravascular Ultrasound Guided Drug‐Eluting Stents Implantation in “All‐Comers” Coronary Lesions.Summary of Findings With Quality of EvidenceARR indicates absolute risk reduction; GRADE, Grading of Recommendations, Assessment, Development, and Evaluations; IVI, intravascular imaging; MACEs, major adverse cardiac events; NNT, number needed to treat; PCI, percutaneous coronary intervention; RR, relative risk; TLR, target‐lesion revascularization; and TVR, target‐vessel revascularization.All the estimates are based on direct comparison of absolute event rates from randomized controlled trials with low overall risk of bias. The provided estimates had no important heterogeneity.Across all patients, intravascular imaging–guided PCI conferred a lower risk of MACEs as compared with angiography‐guided PCI (RR, 0.67 [95% CI, 0.55–0.82]; P<0.001; Figure 1). Heterogeneity was I 2=7.7%. In patients who underwent complex PCI, intravascular imaging–guided PCI conferred a lower risk of MACEs as compared with angiography‐guided PCI (RR, 0.61 [95% CI, 0.49–0.74]; P<0.001; Figure S3). There was no important heterogeneity (I 2=0.0%), with no differences in patients undergoing noncomplex PCI (Figure S3). Meta‐regression identified a significant association between complex PCI and MACEs (P interaction=0.03; Tables S8 and S9).AIR‐CTO indicates angiographic and clinical comparisons of intravascular ultrasound‐ versus angiography‐guided drug‐eluting stent implantation for patients with chronic total occlusion lesions; AVIO, angiography vs intravascular ultrasound optimization trial; CTO‐IVUS, impact of intravascular ultrasound‐guided chronic total occlusion intervention with drug‐eluting stents; DOCTORS, optical coherence tomography to optimize results of percutaneous coronary intervention in patients with non‐ST‐elevation acute coronary syndrome; HOME DES IVUS, long‐term health outcome and mortality evaluation after invasive coronary treatment using drug eluting stents with or without the intravascular ultrasound guidance trial; ILUMIEN III, OPTIMIZE PCI, optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation; iSIGHT, optical coherence tomography versus intravascular ultrasound and angiography to guide percutaneous coronary interventions; IVUS‐XPL, effect of intravascular ultrasound–guided vs angiography‐guided everolimus‐eluting stent implantation; MACEs indicates major adverse cardiac events; OCTACS, optical coherence tomography guided percutaneous coronary intervention with nobori stent implantation in patients with non‐ST‐segment‐elevation myocardial infarction trial; PCI, percutaneous coronary intervention; RENOVATE‐COMPLEX‐PCI, randomized controlled trial of intravascular imaging guidance versus angiography‐guidance on clinical outcomes after complex percutaneous coronary intervention; RESET, real safety and efficacy of a 3‐month dual antiplatelet therapy following zotarolimus‐eluting stents implantation) trial; ROBUST, OCT guidance during stent implantation in primary PCI trial; and ULTIMATE, intravascular ultrasound guided drug‐eluting stents implantation in “all‐comers” coronary lesions.Across all patients, intravascular imaging–guided PCI conferred a lower risk of cardiac death compared with angiography‐guided PCI (RR, 0.49 [95% CI, 0.34–0.71]; P<0.001; Figure 2). There was no important heterogeneity (I 2=0.0%). In patients who underwent complex PCI, intravascular imaging–guided PCI conferred a lower risk of cardiac death compared with angiography‐guided PCI (RR, 0.44 [95% CI, 0.28–0.68]; P<0.001; Figure S4). There was no important heterogeneity (I 2=0.0%), with no significant differences among patients who underwent noncomplex PCI (Figure S4). Meta‐regression did not identify a significant association between complex PCI and cardiac death (P interaction=0.97; Tables S8 and S9).PCI indicates percutaneous coronary intervention.Across all patients, the point estimate for all‐cause death with intravascular imaging–guided PCI compared with angiography‐guided PCI was a RR of 0.81 (95% CI, 0.61–1.07; P=0.14; Figure 3). There was no important heterogeneity (I 2=0.0%). In patients who underwent complex PCI, the point estimate for all‐cause death with intravascular imaging–guided PCI compared with angiography‐guided PCI was a RR of 0.75 (95% CI, 0.55–1.02; P=0.07; Figure S5). There was no important heterogeneity (I 2=0.0%). Meta‐regression did not identify a significant association between complex PCI and all‐cause death (P interaction=0.32; Tables S8 and S9).PCI indicates percutaneous coronary intervention.Across all patients, the point estimate for MI with intravascular imaging–guided PCI compared with angiography‐guided PCI was a RR of 0.82 (95% CI, 0.62–1.07; P=0.14; Figure 4). There was no important heterogeneity (I 2=0.6%). In addition, the point estimate for spontaneous MI was a RR of 0.52 (95% CI, 0.27–1.03; P=0.06) and for periprocedural MI was a RR of 0.91 (95% CI, 0.55–1.53; P=0.73) when intravascular imaging–guided PCI was compared with angiography‐guided PCI. There was no important heterogeneity for spontaneous MI (I 2=0.0%), however, for periprocedural MI (I 2=40.9%; Table S10). There were no differences in MI among patients who underwent complex PCI or noncomplex PCI (Figure S6). Meta‐regression did not identify a significant association between complex PCI and MI (P interaction=0.63; Tables S8 and S9).MI indicates myocardial infarction; and PCI, percutaneous coronary intervention.Across all patients, intravascular imaging–guided PCI conferred a lower risk of TLR compared with angiography‐guided PCI (RR, 0.67 [95% CI, 0.49–0.91]; P=0.01; Figure 5). There was no important heterogeneity (I 2=0.0%). In patients who underwent complex PCI, intravascular imaging–guided PCI conferred a lower risk of TLR compared with angiography‐guided PCI (RR, 0.61 [95% CI, 0.44–0.86]; P=0.005; Figure S7). There was no important heterogeneity (I 2=0.0%). There were no significant differences in TLR in patients who underwent noncomplex PCI (Figure S7). Meta‐regression did not identify a significant association between complex PCI and TLR (P interaction=0.35; Tables S8 and S9).PCI indicates percutaneous coronary intervention.Across all patients, intravascular imaging–guided PCI conferred a lower risk of TVR compared with angiography‐guided PCI (RR, 0.60 [95% CI, 0.45–0.80]; P<0.001; Figure 5). There was no important heterogeneity (I 2=0.0%). In patients who underwent complex PCI, intravascular imaging–guided PCI conferred a lower risk of TVR compared with angiography‐guided PCI (RR, 0.59 [95% CI, 0.45–0.79]; P<0.001; Figure S8). There was no important heterogeneity (I 2=0.0%).Among all patients, intravascular imaging–guided PCI conferred a lower risk of stent thrombosis (RR, 0.63 [95% CI, 0.40–0.99]; P=0.046) compared with angiography‐guided PCI. There was no important heterogeneity (I 2=2.6%; Figure 6).PCI indicates percutaneous coronary intervention.Among all patients, intravascular imaging–guided PCI conferred a lower risk of target‐vessel failure (RR, 0.62 [95% CI, 0.49–0.79]; P<0.001; I 2=0.0%), target vessel MI (RR, 0.61 [95% CI, 0.42–0.89]; P=0.01; I 2=0.0%), and clinical TLR (RR, 0.60 [95% CI, 0.44–0.82]; P=0.001; I 2=0.0%) compared with angiography‐guided PCI (Figure 4; Figure S9). There was no important heterogeneity for all these outcomes. The results for other secondary outcomes are provided in Table S10.The forest plots for the meta‐analyses of trials of IVUS and OCT considered separately are shown in Figures S10 through S17. The subgroup analysis with interaction testing based on the type of clinical presentation and follow‐up duration of RCTs are summarized in Tables S11 and S12. There was no significant interaction between type of presentation (acute coronary syndrome versus stable coronary artery disease) or follow‐up duration for any of the assessed outcomes.A jackknife sensitivity analysis excluding each trial in turn for all primary end points revealed broadly consistent results, as shown in Tables S13 through S18. Additional sensitivity analysis was performed using fixed effects for each of the main primary outcomes with consistent results similar to the primary analysis, as shown in Tables S19 through S23. The sensitivity analyses using the Fisher exact test yielded concordant results for all outcomes (Tables S19 through S23). The additional analyses using the stricter definition of complex PCI (chronic total occlusions, left main PCI, and the complex PCI subgroup of ULTIMATE) demonstrated results consistent with the main complex PCI subgroup analysis (Figures S18 through S24).

    Discussion

    The present study represents the most contemporary systematic review and meta‐analysis of intravascular imaging–guided PCI and incorporates the totality of the randomized data available with 16 included trials and 7814 patients. The principal findings of this study (summarized in Figure 7) are that an intravascular imaging–guided approach, as compared with using angiography alone, improves clinical outcomes, with a 33% reduction in MACEs, 51% reduction in cardiac death, 37% reduction in stent thrombosis, 33% reduction in TLR, 40% reduction in TVR, and 39% reduction in target‐vessel MI. The magnitude of these benefits is large, and statistical heterogeneity was absent or low for all analyses, indicating a consistency of effect across studies. Meta‐regression analysis did suggest a significant interaction between complex PCI and MACEs, indicating that complexity of PCI moderates the observed relationship between intravascular imaging and MACEs and further reinforcing the increased clinical benefit of intravascular imaging in the most complex patients. We believe these findings are sufficient to lead to changes in guideline recommendations with class I recommendations for an intravascular imaging–guided approach for PCI, especially for complex lesion subsets.PCI indicates percutaneous coronary intervention.Our analysis differs from prior published meta‐analytic work in several ways.10, 11, 12, 13, 14, 15, 17, 40 First, it includes newly available trial data with the publication of 1 new large trial and longer‐term follow‐up from 2 other trials. Second, we were able to obtain additional previously unpublished data from the principal investigators of some trials for certain outcomes and subgroups, ensuring that this study is the most exhaustive and complete representation of the existing trial data in the field (Table S6). Third, we excluded observational studies, which are susceptible to bias in the form of both measured and unmeasured confounders. Fourth, we considered all trials of intravascular imaging together irrespective of the imaging modality, as we believe it is the use of an image‐guided approach that will improve outcomes rather than the use of one imaging modality above another. Fifth, we specifically examined the most complex lesion subsets, for which it has been assumed the benefit of intravascular imaging is greatest.Improved clinical outcomes with an intravascular imaging–guided approach are likely a result of implantation of larger stents with greater final minimal stent areas achieved, as well as avoiding significant plaque burden at the edges of stents and untreated edge dissections. Clinical outcomes with an intravascular imaging–guided approach may be further improved with establishing criteria for an optimal stent result such as that used in the ULTIMATE trial, in which the clinical benefit was determined by achieving optimal stent expansion, defined as minimal stent area >90% distal reference luminal area or an overall minimal stent area ≥5 mm2.2 Conversely, these clinical benefits were obviated if these criteria were not achieved. Further improvements in clinical outcomes with an imaging‐guided approach could be achieved by establishment of key benchmarks for an optimal stent result by imaging criteria.The magnitude of benefit of an intravascular imaging–guided approach is large, with a one‐third reduction in MACEs, one‐third reduction in TLR, 40% reduction in stent thrombosis and TVR, and, most strikingly, a 50% reduction in cardiac death. By way of comparison, drug‐eluting stents as compared with bare‐metal stents were associated with a possible slight (but statistically nonsignificant) 11% reduction in cardiac death as compared with bare‐metal stents in an individual patient meta‐analysis of 20 RCTs.41 Drug‐eluting stent use, as compared with bare‐metal stents, is associated with 37% reductions in stent thrombosis and 45% reductions in TVR, which are findings similar to those observed with imaging‐guided PCI as compared with angiography‐guided PCI. Drug‐eluting stent use receives class I recommendations from guidelines. The clinical benefits of imaging guidance come with no downside or trade‐off, aside from the cost of the imaging catheter and a small, insignificant increase in procedural time. Our analysis suggests that the benefit of intravascular imaging is greatest in complex lesion subsets, and in terms of economic implications and resource use, an initial focus on complex lesions might be most appropriate.Our analysis suggests a potential benefit in terms of all‐cause death, although this result was not statistically significant. Across all patients, the point estimate for all‐cause death for intravascular imaging as compared with angiography was a RR of 0.81 (95% CI, 0.61–1.07; P=0.14), and for complex lesion subsets, the point estimate was a RR of 0.75 (95% CI, 0.55–1.02; P=0.07). We believe that a therapy that significantly reduces MACEs, cardiac death, stent thrombosis, TLR, TVR, and target‐vessel MI to the extent that intravascular imaging does is very likely to lead to reductions in all‐cause death, but our present analysis is underpowered to demonstrate a statistically significant benefit. With the addition of new trials with increased patients and events, it is likely that the precision around the point estimates will increase and the reduction in death will become statistically significant. These new trials are forthcoming, including ILUMIEN IV (Optical Coherence Tomography [OCT] Guided Coronary Stent Implantation Compared to Angiography: A Multicenter Randomized Trial in PCI; NCT03507777), OCTOBER (European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction; NCT03171311), IMPROVE (Impact on Revascularization Outcomes of Intravascular Ultrasound‐Guided Treatment of Complex Lesions and Economic Impact Trial; NCT04221815), and OPTIMAL (Optimization of Left Main PCI With Intravascular Ultrasound Trial; NCT04111770).42, 43, 44, 45, 46, 47, 48, 49This is a study‐level meta‐analysis, and individual patient data were not available to us. This prevents us from performing more granular subgroup analyses or assessing temporality of events with Kaplan–Meier plots and landmark analyses. Many trials did not report hazard ratios, which are the most appropriate method for analyzing survival data and account for varying follow‐up durations. To help overcome this, we also performed analyses at varying time early intervals. Definitions of clinical outcomes and subgroups are never entirely consistent across included trials, which is a problem common to all meta‐analyses. This problem will only be overcome when trialists commit to standardizing end point definitions and subgroups across all trials to facilitate better synthesis of pooled data. However, statistical heterogeneity was absent or low for the majority of our meta‐analyses. Follow‐up duration of most trials was relatively short, limiting our ability to study the longer‐term impact of intravascular imaging when compared with angiography. We would expect longer‐term follow‐up to lead to accrual of events with subsequent increasing of precision and narrowing of CIs, but this cannot be studied from the available data. Randomization is the only way to avoid bias from measured and unmeasured confounders when assessing an effect of therapy, and we therefore limited our analysis to randomized trials, which necessarily exclude all patients who do not meet their narrow eligibility criteria and can limit generalizability. The larger RCTs in this analysis are primarily based on study populations from countries like China or South Korea, where adoption of intravascular imaging is higher, and familiarity with image interpretation to guide intervention is likely to be present.2, 4, 5 This may somewhat limit generalizability of their results to other regions where adoption is lower. Our definition of complex PCI was based in large part on the recent RENOVATE‐COMPLEX‐PCI trial, but led to the majority of lesions in this study being classified as complex, which may not be representative of clinical practice in most settings. We also used an additional, stricter definition of complex PCI to include left main lesions, chronic total occlusions, and the complex PCI cohort from ULTIMATE, which demonstrated consistent results.

    Conclusions

    In patients undergoing PCI, intravascular imaging is associated with a significant reduction in MACE, cardiac death, stent thrombosis, TLR, and TVR. The magnitude of benefit is large and consistent across all included studies. There may also be benefits in all‐cause death, particularly in complex lesion subsets. These results support the use of intravascular imaging as the standard of care for all patients undergoing PCI, providing a compelling argument for upgraded guideline recommendations that reflect the totality of contemporary randomized evidence.

    Sources of Funding

    Dr Howard is funded by the British Heart Foundation (FS/ICRF/22/26039).

    Disclosures

    Dr Mintz reports receiving honoraria from Boston Scientific, Philips Volcano, Medtronic, and Terumo. Dr Moses holds equity in Xenter, Covanos, and Orchestra. Dr Chen has received speaker honoraria from Microport, Pulnovo, Boston International Scientific, Medtronic, Sinofi, and BioMed. Dr Shao‐Liang Chen is a fellow at the Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, Nanjing, China. Dr Chen received the grants from the National Scientific Foundation of China. Dr Nanna reports current research support from the American College of Cardiology Foundation supported by the George F. and Ann Harris Bellows Foundation, the Patient‐Centered Outcomes Research Institute, the Yale Claude D. Pepper Older Americans Independence Center (P30AG021342), and the National Institute on Aging/National Institutes of Health from R03AG074067 (GEMSSTAR award); and consulting fees from HeartFlow Inc. Dr Maehara has served as a consultant for Boston Scientific, Philips, and Shockwave Medical; and has served on the Advisory Board of SpectraWave. Dr Ali reports institutional grant support from Abbott, Abiomed, Acist Medical, Boston Scientific, Cardiovascular Systems Inc, Medtronic Inc, National Institute of Health, Opsens Medical, and Philips; and consulting fees from AstraZeneca, Philips, Shockwave, Equity in Elucid, Lifelink, Spectrawave, Shockwave, and VitalConnect. Dr Leon has received research support to his institution from Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott; and has served on advisory boards for Medtronic, Boston Scientific, Gore, Meril Lifescience, and Abbott. Dr Ahmad is a consultant for Cardiovascular Systems Inc and Shockwave and serves on the Medical Advisory Board of Boston Scientific. The remaining authors have no disclosures to report.

    Supporting information

    Tables S1–S23Figures S1–S24
    AMDr. Aaqib Malik

    Dr. Aaqib Malik

    Cardiology · Interventional & Complex Coronary
    aaqib